Core Insights - Whitehawk Therapeutics will present its next-generation antibody-drug conjugate (ADC) portfolio at the AACR Annual Meeting 2026, showcasing three preclinical abstracts [1][2] Company Overview - Whitehawk Therapeutics is a clinical-stage oncology therapeutics company focused on advanced technologies to enhance cancer treatments [4] - The company has developed a three-asset ADC portfolio designed to address limitations of first-generation ADCs, aiming to significantly impact patients with difficult-to-treat cancers [4] ADC Programs - The three ADC programs being presented are HWK-007, HWK-016, and HWK-206, each utilizing novel bioconjugation and linker-payload technology [2][3] - HWK-016 targets MUC16, HWK-007 targets PTK7, and HWK-206 targets SEZ6, with presentations scheduled for April 19 and April 21, 2026 [3] Preclinical Data - The preclinical data indicate a potential best-in-class therapeutic index among next-generation TOP1i-based ADCs, demonstrating high potency and tumor regressions at low doses [2] - In non-human primate studies, the ADCs showed high tolerability with a highest non-severely toxic dose (HNSTD) of 60 mg/kg, supported by a low free payload in circulation [2]

Core Viewpoint - Defence Therapeutics Inc. is launching a private placement to raise up to $11,000,000 through the issuance of 20,000,000 units at a price of $0.55 per unit, each consisting of one common share and one warrant [1] Group 1: Private Placement Details - The private placement aims to raise aggregate gross proceeds of $6,000,000 (CAD) from two institutional investors, with proceeds deposited in escrow prior to closing [2] - Upon closing, the units will be released from escrow, and the investors' proceeds will be provided to the company in monthly cash tranches of $333,333 (CAD) over an 18-month period [2][3] - The company will release shares in equal monthly installments of approximately 606,060 shares over the 18-month term, contingent upon cash payments [3] Group 2: Warrant and Fee Structure - A total of 10,909,091 warrants will be issued, exercisable at $0.65 (CAD) per share for 24 months, with an equity blocker provision limiting ownership to 9.99% of outstanding shares [4] - Investors will receive a corporate finance fee of $360,000 (CAD), payable in cash or through the issuance of 654,546 units at the private placement price [5] Group 3: Use of Proceeds - The proceeds from the private placement will be utilized to advance the company's Antibody Drug Conjugate (ADC) and Radiopharmaceutical programs, develop partnerships, and for working capital [6] Group 4: Regulatory and Compliance Information - All securities issued under the private placement will be subject to resale restrictions in accordance with Canadian securities laws, with the closing expected around March 6, 2026, pending CSE approval [7]

Core Insights - Ipsen has secured a licensing deal for a Chinese-developed antibody drug conjugate (ADC) that could exceed $1 billion, highlighting the growing significance of ADCs in the oncology sector in 2025 [1][2]. Company Summary - Ipsen has signed a licensing agreement with Simcere Zaiming for the ADC asset SIM0613, which is set to begin clinical development in 2026. The deal grants Ipsen global rights for the cancer treatment outside of Greater China, with potential payments to Simcere Zaiming reaching $1.06 billion [2]. - Ipsen will manage manufacturing rights and oversee Phase I preparation activities, including regulatory submissions. The therapy has shown promising results in preclinical models, with plans for a Phase I trial in cancer patients anticipated in the second half of 2026 [3]. - SIM0613 targets the LRRC15 protein, which is highly expressed in various tumor types and cancer-associated fibroblasts, while exhibiting limited expression in normal cells, allowing for a targeted approach in killing cancer cells [4]. - Ipsen has been actively expanding its oncology portfolio, adding over 20 early-stage programs since 2020, and aims to position itself as a leader in the oncology market [5]. Industry Summary - The ADC market is experiencing rapid growth, with projected revenues expected to exceed $45 billion by 2030, indicating a strong investment trend among pharmaceutical companies [6]. - Major pharmaceutical companies, including Boehringer Ingelheim and Roche, have made significant investments in ADC technologies this year, reflecting the competitive landscape and the increasing importance of ADCs in cancer treatment [7].